Abstract: Dry powder formulations for inhalation containing a combination of an anti-cholinergic, a long-acting beta2-adrenoceptor agonist, and a corticosteroid are useful for the prevention and/or treatment of an inflammatory and/or obstructive airways disease.
Type:
Application
Filed:
August 27, 2018
Publication date:
December 20, 2018
Applicant:
CHIESI FARMACEUTICI S.P.A.
Inventors:
Claudio CAFIERO, Leonardo ORTENZI, Francesca J. SCHIARETTI
Abstract: Compositions and methods for making a pharmaceutical dosage form include making a pharmaceutical composition that includes one or more active pharmaceutical ingredients (API) with one or more pharmaceutically acceptable excipients by thermokinetic compounding into a composite. Compositions and methods of preprocessing a composite comprising one or more APIs with one or more excipients include thermokinetic compounding, comprising thermokinetic processing the APIs with the excipients into a composite, wherein the composite can be further processed by conventional methods known in the art, such as hot melt extrusion, melt granulation, compression molding, tablet compression, capsule filling, film-coating, or injection molding.
Type:
Application
Filed:
June 19, 2018
Publication date:
December 20, 2018
Applicants:
BOARD OF REGENTS, THE UNIVERISTY OF TEXAS SYSTEM, DISPERSOL TECHNOLOGIES, LLC
Inventors:
Chris BROUGH, James W. MCGINITY, Dave A. MILLER, James C. DINUNZIO, Robert O. WILLIAMS, III
Abstract: Compositions and methods for treating addiction in a subject are disclosed. In particular, compositions and methods for treating addiction to a dopaminergic psychostimulant are disclosed. In some embodiments, addiction is treated by agonizing bile acid receptors in the subject. For example, in some embodiments, the method comprises administering to the subject a therapeutically effective amount of a composition comprising a therapeutically effective amount of a bile acid receptor agonist. In some embodiments, the method comprises surgically diverting bile acids in the subject in a manner suitable to increase circulating bile acids in the subject.
Type:
Application
Filed:
August 30, 2018
Publication date:
December 20, 2018
Inventors:
Aurelio Galli, Heinrich J.G. Matthies, Naji N. Abumrad, India A. Reddy, Charles Robb Flynn, Kevin Erreger
Abstract: This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.
Type:
Application
Filed:
July 31, 2018
Publication date:
December 20, 2018
Inventors:
Randice Lisa Altschul, Neil David Theise, Myron Rapkin, Rebecca O'Brien
Abstract: Described herein are combination therapies for cancer (such as lymphoid malignancies) and immune diseases (such as autoimmune diseases and inflammatory diseases). The therapies comprise the combined use of inhibitors of BTK, mTOR kinase, and Bcl-2 or their signaling pathways, and immunomodulatory drugs. Also described are pharmaceutical compositions and kits comprising these inhibitors.
Abstract: The present invention relates to uses of ether phospholipids in treating and preventing various diseases, including, but not limited to, neurodegenerative or brain diseases such as Alzheimer's disease, cognitive impairment, brain fatigue, Parkinson disease, depression, anxiety disorder, insomnia and schizophrenia; metabolic syndrome such as diabetes and obesity; various infectious diseases such as viral diseases; diseases related to inflammation; heart diseases, and immune disorders. Preferably, the ether phospholipids are derived from extracting bivalves, which provides superior efficacies in treating and preventing the diseases.
Type:
Application
Filed:
June 16, 2017
Publication date:
December 20, 2018
Applicant:
Institute of Rheological Functions of Food
Abstract: The present invention is related to a pharmaceutical formulation in the form of a sachet which comprises ascorbic acid and phosphomycine trometamol, to be used in treating urinary system infections caused by pathogens sensitive to phosphomycine. The formulation is characterized in that phosphomycine is enabled to be more efficient in treating urinary system infections depending on the fact that ascorbic acid reduces the pH of urine.
Abstract: A compound of Formula (II): for use in the prevention or treatment of a bacterial infection.
Type:
Application
Filed:
December 2, 2016
Publication date:
December 20, 2018
Applicant:
Auspherix Limited
Inventors:
Ian HOLMES, Alan NAYLOR, Dagmar ALBER, Jonathan Raymond POWELL, Meriel Ruth MAJOR, Gabriel NEGOITA-GIRAS, Daniel Rees ALLEN, Lucie Juliette GUETZOYAN, Nigel Paul KING
Abstract: Provided herein are heterocyclic compounds and pharmaceutical formulations that can be used to treat bacterial infections. Also provided herein are methods of making and using the heterocyclic compounds and pharmaceutical formulations.
Type:
Application
Filed:
July 31, 2018
Publication date:
December 20, 2018
Inventors:
Yu Chen, Orville Antonio Pemberton, Adam Renslo, Priyadarshini Jaishankar
Abstract: Neridronic acid, in an acid or a salt form, can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.
Abstract: The present disclosure relates, inter alia, to compositions and methods for treating viral diseases and cancer. There are disclosed lipophilic antiviral and anticancer acyclic nucleoside phosphonate diesters, preparation thereof, and methods of using the compounds to treat viral diseases and cancer.
Type:
Application
Filed:
August 24, 2018
Publication date:
December 20, 2018
Inventors:
Karl Y. Hostetler, James R. Beadle, Nadejda Valiaeva
Abstract: The invention relates to methods of treating cancer, with a combination of an arginase inhibitor and a chemotherapeutic agent. The invention further relates to methods of assessing efficacy of a cancer treatment by measuring arginine levels in a tumor.
Type:
Application
Filed:
August 27, 2018
Publication date:
December 20, 2018
Inventors:
Matthew I. GROSS, Susanne M. STEGGERDA, Weiqun LI
Abstract: An antimicrobial product and methods of use are provided. The antimicrobial product includes a water-soluble antimicrobial organosilane and various additional compound, including antibiotic and anti-inflammatory medications, antiseptics, and/or detergents. An example delivery system including a microcapsule encasing the product is also described. Methods of use include embedding a delivery system within an article, such as bandages, inserts or wound coverings, the microcapsule containing the product which is released by a mechanism and at a time particular to the intended use of the article. The methods include treating an infection on a substrate by disrupting an existing microbial colonization, penetrating existing biofilms, and/or killing existing microbes.
Abstract: The present invention relates to agents that induce mitochondrial unfolded protein response (UPR mt) in muscle stem cells and prevents or reverse process of muscle stem cell senescence. Further, the invention relates to methods and compositions useful in the prevention and/or treatment of muscle stem senescence.
Type:
Application
Filed:
September 7, 2016
Publication date:
December 20, 2018
Inventors:
HONGBO ZHANG, KEIR MENZIES, JOHAN AUWERX, DONGRYEOL RYU
Abstract: The present invention discloses a medicament for the prevention and treatment of tumors, in particular relating to the use of 8-oxo-deoxyguanosine triphosphate (8-oxo-dGTP) in the manufacturing of a medicament for the prevention and treatment of tumors, and a medicament comprising 8-oxo-dGTP for the prevention and treatment of tumors, and falls within the pharmaceutical field. The 8-oxo-dGTP can be used in the manufacturing of a medicament for at least one of the treatment, prevention and control of tumors. The 8-oxo-dGTP has a significant inhibitory effect on tumorigenesis and tumor cell proliferation for many types of tumors, and can serve as a new candidate medicament for the prevention and treatment of tumors. Animal experiments show that the 8-oxo-dGTP is significantly superior to 5-FU in terms of tumor inhibition, therefore has a good industrial availability and great business and social values.
Abstract: Provided herein are systems for treating a subject with a pulmonary infection, for example, a nontuberculous mycobacterial pulmonary infection, a Burkholderia pulmonary infection, a pulmonary infection associated with bronchiectasis, or a Pseudomonas pulmonary infection. The system includes a pharmaceutical formulation comprising a liposomal aminoglycoside dispersion, and the lipid component of the liposomes consist essentially of electrically neutral lipids. The system also includes a nebulizer which generates an aerosol of the pharmaceutical formulation at a rate greater than about 0.53 gram per minute. The aerosol is delivered to the subject via inhalation for the treatment of the pulmonary infection.
Type:
Application
Filed:
June 15, 2018
Publication date:
December 20, 2018
Inventors:
Walter Perkins, Vladimir Malinin, Xingong Li, Brian Miller, Dominique Seidel, Philipp Holzmann, Harald Schulz, Michael Hahn
Abstract: An object of the present invention is to provide a liquid medicinal preparation which does not generate precipitates and is suitable for mass production. According to the present invention, provided is a liquid medicinal preparation that contains 1-(2-deoxy-2-fluoro-4-thio-?-D-arabinothranosyl)cytosine or a salt thereof, a polyhydric alcohol having a molecular weight of 100 or less, and water. The polyhydric alcohol is preferably glycerin, propylene glycol, or butanediol.
Abstract: In some embodiments, the invention is directed to a method for diagnosing fibrosis and/or fibrosis related diseases and to a method for screening a pharmaceutically active compound for the treatment of fibrosis and/or fibrosis related diseases. The present invention further relates to compositions for use in the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions modulate the activity of a miRNA for the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions inhibit the activity of miR-21 for the treatment, amelioration, and/or prevention of fibrosis.
Abstract: Described herein are compositions comprising shortened fibers of poly-N-acetylglucosamine and/or a derivative thereof (“sNAG nanofibers”) and the use of such compositions in the treatment of various diseases, in particular, diseases associated with decreased tensile strength of tissue, decreased elasticity of tissue, increased collagen content or abnormal collagen content in tissue, abnormal alignment of collagen in tissue, and/or increased myofibroblast content in tissue.
Type:
Application
Filed:
December 14, 2017
Publication date:
December 20, 2018
Applicant:
Marine Polymer Technologies, Inc.
Inventors:
Sergio Finkielsztein, John N. Vournakis
Abstract: The invention relates to an oral formulation for targeted delivery of cholestyramine to the colon, comprising a plurality of cholestyramine pellets that are coated with a diffusion-controlled inner coating and an enteric outer coating. The invention also relates to the use of this formulation in the treatment of bile acid malabsorption.
Type:
Application
Filed:
May 24, 2018
Publication date:
December 20, 2018
Inventors:
Per-Göran Gillberg, Nils OVe Gustafsson, Nils-Olof Lindberg, Jessica Elversson
Abstract: The invention relates to an oral formulation for targeted delivery of cholestyramine to the colon, comprising a plurality of cholestyramine pellets that are coated with a colon release coating. The invention also relates to the use of this formulation in the treatment of bile acid malabsorption.
Type:
Application
Filed:
May 24, 2018
Publication date:
December 20, 2018
Inventors:
Per-Göran Gillberg, Nils Ove Gustafsson, Nils-Olof Lindberg, Jessica Elversson
Abstract: The invention relates to an oral formulation for targeted delivery of cholestyramine to the colon, comprising a plurality of cholestyramine pellets that are coated with a colon release coating. The invention also relates to the use of this formulation in the treatment of bile acid malabsorption.
Type:
Application
Filed:
May 24, 2018
Publication date:
December 20, 2018
Inventors:
Per-Göran Gillberg, Nils Ove Gustafsson, Nils-Olof Lindberg, Jessica Elversson
Abstract: Provided is a tear lipid layer stabilizer that is capable of stabilizing a tear lipid layer and allowing the tear lipid layer to sufficiently spread over a corneal surface, to thereby prevent the evaporation of a tear aqueous layer on the corneal surface, and hence is suitable for amelioration, alleviation, or treatment of evaporative dry eye symptoms caused by Meibomian gland dysfunction, an ophthalmic solution having blended therein the tear lipid layer stabilizer, and a tear lipid layer-stabilizing method using the tear lipid layer stabilizer. The tear lipid layer stabilizer includes a copolymer that has a weight-average molecular weight of from 10,000 to 5,000,000, and contains 10 mol % to 90 mol % of a constituent unit (A) based on 2-(meth)acryloyloxyethyl phosphorylcholine and 90 mol % to 10 mol % of a constituent unit (B) based on an alkyl group-containing (meth)acrylic monomer.
Type:
Application
Filed:
December 21, 2016
Publication date:
December 20, 2018
Applicant:
NOF Corporation
Inventors:
Shunsuke SAKURAI, Koji MIYAMOTO, Yoshihisa SHIMAMURA, Nobuyuki YAMAMOTO
Abstract: Disclosed herein are methods for treating acute or chronic heart failure using inorganic nitrite, such as sodium nitrite. Sodium nitrite is a naturally occurring compound that is commonly used as a preservative in meats. Due to its vasodilative properties and involvement in the nitric oxide pathway, drug development companies and researchers are also investigating sodium nitrite as a therapeutic agent.
Type:
Application
Filed:
April 16, 2018
Publication date:
December 20, 2018
Inventors:
Mark Thomas Gladwin, Hunter Clay Champion, Edwin Parsley
Abstract: The present invention relates to the use of thiosulfate to potentiate the anti-pathogenic effect of lactobacilli bacteria, the thiosulfate being in a quantity of at least 100 mg for 107 to 1010 CFU of lactobacilli. The invention also relates to a pharmaceutical composition including at least 100 mg of thiosulfate per gram, in combination with a Lactobacillus crispatus strain, and to its use in the treatment of urogenital infections such as vaginosis, candidosis and urinary tract infections.
Abstract: Medical use of natural and synthetic zeolites for treatment, prevention, and palliation in humans or animals of deleterious concentrations of ammonia, mercaptans, heavy metals and other toxins by oral administration.
Abstract: Described herein are methods for the preparation of stable semi-mature tolerogenic dendritic cells and compositions comprising such stable semi-mature tolerogenic dendritic cells. The stable semi-mature tolerogenic dendritic cells described herein and compositions thereof can be used for the establishment of immune tolerance when treating an autoimmune disease, graft rejection and/or graft-versus-host disease.
Abstract: The present invention relates to methods for expanding a population of alveolar macrophages in a long term culture. In particular, an object of the present invention relates to a method of expanding a population of alveolar macrophages in a long term culture comprising culturing the population of alveolar macrophages in a culture medium supplemented with an amount of GM-CSF.
Type:
Application
Filed:
December 8, 2016
Publication date:
December 20, 2018
Inventors:
Michael SIEWEKE, Kaaweh MOLAWI, Laufey GEIRSDOTTIR
Abstract: A method comprising obtaining a first cell sample from a first subject; obtaining a second cell sample from a second subject; culturing the first cell sample in the presence of at least a portion of a culture media of the second cell sample for a time period ranging from about 24 hours to about 6 weeks to produce a restoring composition; and contacting the restoring composition with the second cell sample for a period of time ranging from about 24 hours to about 6 weeks to produce a restored composition.
Abstract: Immune-potentiating compositions include cells exhibiting enhanced antigen-presenting functions. The compositions are generally useful in facilitating the stimulation of host immune cell responses, including selective and targeted immune cell responses, and are particularly useful in the treatment and/or prophylaxis of cancers, tumors and pathogenic infections.
Abstract: The presently disclosed subject matter provides for methods and compositions for treating multiple myeloma. It relates to chimeric antigen receptors (CARs) that specifically target B cell maturation antigen (BMCA), and immunoresponsive cells comprising such CARs. The presently disclosed BMCA-specific CARs have enhanced immune-activating properties, including anti-tumor activity.
Type:
Application
Filed:
January 19, 2018
Publication date:
December 20, 2018
Applicants:
MEMORIAL SLOAN KETTERING CANCER CENTER, EUREKA THERAPEUTICS, INC.
Inventors:
Renier J. Brentjens, Eric L. SMITH, Cheng LIU
Abstract: Contemplated immunotherapies include co-administration of an activated NK cell that is further genetically modified and a cancer therapeutic agent. In preferred embodiments, activated NK cells are further modified to taNK cells, which include a chimeric antigen receptor (CAR) with affinity for a cancer specific antigen, a cancer associated antigen, or a tumor specific antigen. Activated NK cells can also be further genetically modified to include high affinity Fc receptor CD16a (V158). Appropriate cancer therapeutic agents include chemotherapeutic drugs (e.g., nant-paclitaxel) or cancer targeted antibodies (e.g., trastuzumab).
Type:
Application
Filed:
December 9, 2016
Publication date:
December 20, 2018
Inventors:
Shahrooz Rabizadeh, Patrick Soon-Shiong, Hans Klingemann
Abstract: Disclosed are method of enhancing perispinal perfusion in a patient suffering from reduced perfusion of the lower back through administration of T regulatory cells alone capable of stimulating angiogenesis directly or through enhancement of angiogenic activities of cellular therapies. Said cellular therapies possessing angiogenic activities include mesenchymal stem cells, hematopoietic stem cells and endothelial progenitor cells. In one embodiment of the invention, administration of T regulatory cells is performed that are expanded ex vivo. For certain embodiment of the invention T regulatory cells may be autologous or allogeneic.
Abstract: Methods for developing engineered T-cells for immunotherapy that are both non-alloreactive and resistant to immunosuppressive drugs. The present invention relates to methods for modifying T-cells by inactivating both genes encoding target for an immunosuppressive agent and T-cell receptor, in particular genes encoding CD52 and TCR. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.
Type:
Application
Filed:
July 5, 2018
Publication date:
December 20, 2018
Applicant:
Cellectis
Inventors:
Roman GALETTO, Agnes GOUBLE, Stephanie GROSSE, Cecile MANNIOUI, Laurent POIROT, Andrew SCHARENBERG, Julianne SMITH
Abstract: Disclosed herein are cells that are immunoinhibitory cell, which cells recombinantly express a dominant negative form of an inhibitor of a cell-mediated immune response of the cell. In certain embodiments, the immunoinhibitory cell is a regulatory T cell. In another aspect, provided herein is a regulatory T cell that recombinantly expresses a dominant negative form of an inhibitor of a regulatory T cell-mediated immune response. The cells can be sensitized to an antigen that is the target of a pathologic immune response associated with an immune-mediated disorder. Additionally provided are methods of using such cells to treat an immune-mediated disorder in a subject in need thereof.
Abstract: Provided herein are compositions containing an infusion ready population of activated, allogeneic mesenchymal stem cells and one or more pharmaceutically acceptable carriers, diluents, or excipients. Also provided are methods of treating infected wounds in mammals by administering an effective amount of activated mesenchymal stem cells to the mammal.
Type:
Application
Filed:
December 7, 2016
Publication date:
December 20, 2018
Inventors:
Steven W. Dow, Lyndah Chow, Valerie Johnson
Abstract: This invention provides a fluid therapeutic placental product comprising placental cells and a placental dispersion comprising placental factors. The placental cells and the placental dispersion are derived from placental tissue. A placental tissue can optionally be an amnion, chorion, or a trophoblast-depleted chorion. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.
Type:
Application
Filed:
April 10, 2018
Publication date:
December 20, 2018
Inventors:
Samson Tom, Alla Danilkovitch, Dana Yoo, Timothy Jansen, Jin-Qiang Kuang, Jennifer Michelle Marconi
Abstract: Described are methods of isolating high purity myoblasts that are used to create novel DMD model systems and methods using human induced pluripotent stem cells (hiPSCs). Also described are therapeutic methods based on the use of these myoblasts.
Type:
Application
Filed:
December 9, 2016
Publication date:
December 20, 2018
Inventors:
Gabsang Lee, InYoung Choi, HoTae Lim, Kathryn R. Wagner
Abstract: The invention relates to compositions comprising exosomes isolated from hASC and their use in a method of treating brain injury in a subject.
Abstract: The present invention relates to in vitro cultured senescent cells, such as epithelial cells, keratinocytes and/or fibroblasts as well as their use in the treatment of tissue regeneration, particularly for the treatment of wounds such as burns or ulcers or the treatment of inflammatory conditions. Optionally, products may be used in combination with further drugs including antimicrobial or antidiabetic agents.
Abstract: The present invention relates to methods of improving blastocyst implantation by delivering adrenomedullin to the endometrium of a subject. The invention further relates to methods of performing in vitro fertilization.
Abstract: Pharmaceutical compositions are disclosed that includes a therapeutically effective amount of a purified viable Gram negative bacteria and a pharmaceutically acceptable carrier. The pharmaceutical compositions are formulated for topical administration. Methods of treating atopic dermatitis using these pharmaceutical compositions are also disclosed.
Abstract: The present invention relates to methods and compositions for identifying subjects treated with or considered for treatment with checkpoint blockade therapeutic agents that are at higher or lower risk for developing checkpoint therapy associated colitis, by analyzing the intestinal microbiome of those subjects. It is based, at least in part, on the discovery that the abundance of certain intestinal microbiota of the phyla Bacteroidetes, including the bacteria in the families Bacteroidaceae, Rikenellaceae, and Barnesisllaceae, and/or an increase or decrease in microbial genetic pathways involved in polyamine transport and/or B vitamin biosynthesis (e.g., (riboflavin (B2), pantothenate (B5) and thiamine (B1)) are associated with the likelihood of developing checkpoint therapy associated colitis.
Type:
Application
Filed:
May 21, 2018
Publication date:
December 20, 2018
Inventors:
Eric Pamer, Jedd D. Wolchok, Krista Dubin
Abstract: Provided are: a transformation plasmid for transforming anaerobes and enabling highly efficient and stable secretory expression of a target protein; a gene delivery carrier formed from said anaerobes transformed by said plasmid; a pharmaceutical composition including said gene delivery carrier; and a method for diagnosing or treating an ischemic disease utilizing these. Also provided are: a novel secretory signal; a transformation plasmid including said secretory signal; a gene delivery carrier formed from anaerobes transformed by said plasmid; a pharmaceutical composition including said gene delivery carrier; and a method for diagnosing or treating an ischemic disease utilizing these.
Type:
Application
Filed:
January 18, 2016
Publication date:
December 20, 2018
Applicants:
Shinshu University, Anaeropharma Science, Inc.
Abstract: Pharmaceutical preparations include at least one component that enhances sexual response and at least one other compound that enhances sexual sensitivity and pleasure. The component that enhances sexual response enhances blood flow to the genital region. Examples include compounds that dilate blood vessels, such as compounds that increase the amount of nitric oxide (NO) in the blood. The component that enhances sexual sensitivity and pleasure includes one or more cannabinoid compounds from the plant genus Cannabis. Examples include tetrahydrocannabinol (THC), the main psychoactive constituent of Cannabis, and cannabidiol (CBD), which is less or non-psychoactive and modulates THC activity. The ratio of THC/CBD can be selected depending on age, gender, physical health, and/or psychological condition of the user.
Abstract: The present invention relates to a composition for preventing and treating osteoarthritis, which contains a pomegranate concentrate, a eucommia bark extract and an achyranthis radix extract as active ingredients. More specifically, the composite composition of a pomegranate concentrate, a eucommia bark extract and an achyranthis radix extract according to the present invention has a synergistic effect of improving osteoarthritis. In particular, because it can directly protect and regenerate the cartilage and can improve joint stiffness, it can be used in health food, etc.
Type:
Application
Filed:
August 4, 2016
Publication date:
December 20, 2018
Inventors:
Hae-Yeon LEE, Beom-Rak CHOI, Hye-Rim PARK, Seung-Hee KIM
Abstract: Pharmaceutical preparations include at least one component that enhances sexual response and at least one other compound that enhances sexual sensitivity and pleasure. The component that enhances sexual response enhances blood flow to the genital region. Examples include compounds that dilate blood vessels, such as compounds that increase the amount of nitric oxide (NO) in the blood. The component that enhances sexual sensitivity and pleasure includes one or more cannabinoid compounds from the plant genus Cannabis, including extracted compounds, synthetic forms, and derivatives thereof. Examples include tetrahydrocannabinol (THC), the main psychoactive constituent of Cannabis, and cannabidiol (CBD), which is less or non-psychoactive and modulates THC activity. The ratio of THC/CBD can be selected depending on age, gender, physical health, and/or psychological condition of the user.
Abstract: The present invention relates to: a composition comprising a Sicyos angulatus extract or a fraction thereof as an effective ingredient for preventing, alleviating, or treating liver diseases; and a method for preventing or treating liver diseases, comprising a step of administering the composition to a subject suspected of having a liver disease.
Type:
Application
Filed:
December 9, 2016
Publication date:
December 20, 2018
Applicant:
KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
Inventors:
Chul Ho LEE, Yong-Hoon KIM, Jung Ran NOH, Dong Hui CHOI, Jung Hwan HWANG, Kyoung Shim KIM, Yun-Jung SEO, In-Bok LEE, Jung-Hyeon CHOI
Abstract: This present disclosure relates to the use of cranberry derived proanthocyanidins as antibiotic synergizing agent to mitigate multidrug resistance and biofilm formation in different pathogenic bacteria. The synergistic combination of antibiotic and proanthocyanidins could treat bacterial infections using a lower dose of antibiotics to prevent biofilm formation and proliferation of microorganisms, with defined modes of action.